84 results about "Pharmaceutical care" patented technology

A pharmaceutical system and method of operation in which a single remote professional provides pharmaceutical care and oversight of multiple local pharmacies. A control location is connected through an electronic network to one or more individual pharmacies, each of which may be located at a different physical site. Each individual pharmacy includes one or more drug preparation areas, and one or more self-service or staffed customer terminals. A drug preparation area includes a robot, which is adapted to prepare prescriptions or other items, and which is connected by a pneumatic delivery system to one or more customer terminals within the pharmacy.

Described herein is a particular type of pharmaceutical tablet, for oral use, which is formed by one or more layers, and is specifically designed for controlled release of active principles that present problems of bio-availability linked to absorption in the gastro-intestinal tract, and in particular active principles that present an erratic and unpredictable absorption linked to the presence or absence of food at the level of the stomach and/or of the first portion of the small intestine, the said pharmaceutical form being characterized in that it is completely coated with one or more films of a biocompatible and biodegradable polymeric material.

Systems and methods are described for allowing a pharmacist to practice pharmaceutical care in an accurate and efficient manner. The present invention provides the systems for gathering, organizing, and maintaining the necessary clinical and patient data, and providing pharmacists access thereto, through integrated computer software. The clinical data classifies drugs into therapeutic classes, and for each class there is associated therewith known indications, contra-indications, recommended dosages, known adverse reactions, and drug interactions. A clinical database and a patient database are used. In the clinical database, each drug is assigned a unique identification code including a therapeutic cross reference (TXR). The TXR allows access to information associated with the drug's adverse reactions, and dosage recommendations, and also to disease indications and contra-indications via a link to the ICD-9s (International Classification of Diseases) associated with the diseases. The patient data includes patient diagnosis profiles and allergy profiles.

The comprehensive and controlled web-based system facilitates provision of pharmaceutical care and dispensing of medications to patients. The system includes multiple retail or pharmacy outlets whose prescription filling activities are supervised and verified by pharmacists at remote sites. The supervision includes visual confirmation by images for the prescription and the drug dispensed and systematic provision of information pertaining to drug interactions and instructions with affirmative patient confirmation. The system ensures patient safety and education, prescription accuracy, and reduction of expense while assisting rural or economically challenged areas to retain local access to pharmacy services.

The present invention relates to compounds of formula (I):

wherein;

• • R¹ represents hydrogen or C_1-3alkyl;
  • n is an integer having a value of 1 to 5;
  • X represents O or NH;
  • Y represents C or N;

or a pharmaceutically acceptable salt thereof, have been shown to be inducers of human interferon and may possess an improved profile with respect to known inducers of human interferon, for example enhanced potency. The compounds of the invention may therefore be useful in the treatment of various disorders, in particular the treatment of infectious diseases, cancer, allergic diseases and other inflammatory conditions, and their use as vaccine adjuvants.

Disclosed is a method and apparatus for processing pharmaceutical orders to determine whether a buyer of pharmaceuticals qualifies for an “own use” discount. “Own use” discounts on pharmaceuticals are available for a limited class of buyers under 35 U.S.C. §13c. Under one method, an auditor receives an order for a quantity of pharmaceuticals, receives a report associated with the order containing sufficient information therein to perform an audit on the order, and compares the information found in the order with the information found in the associated report to make a status determination as to whether a buyer qualifies for an “own use” discount. Preferably a second report containing additional audit information is received as well. The auditor can also audit the order by comparing the order to this additional information. If these comparisons result in a determination that the buyer does in fact qualify for an “own use” discount, the auditor can then place the order with a pharmaceutical seller for a discounted price. Also disclosed is a pharmaceutical order auditing system that uses a computer to perform the above-described audit.

A method for improving the bioavailability of a bioactive substance includes subjecting the bioactive substance to laser radiation. The laser radiation modifies the bioactive substance to thereby modify reactions relating thereto in the body. The method enables reductions in inflammation associated with autoimmune diseases, modification of reaction by-products in the body, increased homogenization and flattening of molecular shape and improved methylation. The improved methylation can be utilized to reduce homocysteine blood levels, and to reduce anxiety, depression, paranoia, hostility, somatization (perception of bodily distress) and obsessive-compulsive symptoms. Enhanced nitric oxide generation from modified L-arginine can be used to reduce systolic and diastolic blood pressure, lower total and LDL cholesterol levels, and improve the ratio of total to HDL cholesterol. Increased depth of penetration of sparse constructive nodes of laser radiation may increase the range of photodynamic therapy applications and a wide range of in vitro and in vivo modifications of molecular shape and activity. Laser acoustic resonance can be utilized to increase the homogeneity of crystals, or favor the generation of novel or preferred crystalline forms.

Pharmaceutical formulations for treating neurological diseases are described, wherein the formulations comprise a pharmaceutically active agent-transport moiety complex. The formulations are suitable for administration via an intranasal route. Neurological diseases and conditions are associated with reduced brain insulin signaling (i.e., CNS insulin insensitivity), reduced dopaminergic signaling, reduced serotonergic signaling, reduced cholinergic signaling, or reduced GABAergic signaling, and include Alzheimer's disease, Parkinson's disease, epilepsy, neuropathic pain, fibromyalgia, post-herpetic neuralgia, insomnia, or anxiety. Neurological diseases also include cancers of the central nervous system (CNS).

Systems and methods for making and delivering personalized, medically prescribed pharmaceuticals to an individual patient are described. Individual unit doses (IUDs) of medicine may be prepared specific to the individual in need of same, by using a system, which includes a networked control system in combination with manufacturing assemblies specific to the IUDs and delivering the medicine to the patient directly from the manufacturer.

Topical compositions are provided that have 0.5% or more of at least one personal care or pharmaceutical acid, and lightly- to moderately-crosslinked PVP, which is an effective thickener in the low pH systems. In preferred embodiments, the acid is a hydroxy acid and the composition used for personal care, or prescriptive or non-prescriptive medication indications for use on the skin, hair, scalp, foot, or lips. Also provided is the use of the topical compositions to deliver the acid(s) to the skin, hair, scalp, foot, or lips. Especially preferred is a use to reduce irritation and stinging compared to an equivalent compositions not having lightly- to moderately-crosslinked PVP.

The present invention relates to pharmaceutical uses of a Na<+>-coupled HCO3< > transporter (NBC1) N-cyano amide sulfide inhibitor S0859, and provides uses of a Na<+>-coupled HCO3< > transporter (NBC1) N-cyano amide sulfide inhibitor S0859 in preparation of heart failure treating drugs. According to the present invention, the results prove that the inhibitor S0859 can regulate the intracellular calcium ion homeostasis after myocardial infarction, improve ventricular remodeling, and inhibit intracellular calcium overload so as to inhibit ventricular remodeling, such that the invention can provide a new heart failure treating drug so as to effectively delay heart failure and ventricular remodeling caused by myocardial infarction.

The present invention relates to the use of a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone for treating NAFLD/NASH and advanced liver fibrosis by decreased serum cholesterol and triglycerides as well as reducing the content of hepatic fat accumulation, both in the form of macrosteatosis and microsteatosis. Additionally, its use as an agonist for PPARgamma (peroxisome proliferation receptor activated gamma), PPARalpha (peroxisome proliferation receptor activated alpha), LXR and CPT1, key molecules in the metabolism of fatty degradation and inflammation of the liver. In addition, another use is the induction of decreased expression of NFkB master gene, transcriptional inducer of hepatic inflammatory process factor. All of these events results in the reversal of NAFLD/NASH and advanced liver fibrosis.

The present invention describes the use of molecular expression profiles in the primary screening of compounds for pharmacological activity. In some embodiments, the methods of the invention comprise characterizing a profile of expression levels of a number of distinct biological molecules for two distinct sample types (A and B) that differ by some relevant parameter, in order to characterize the difference between the two types in terms of expression profile. Following this, one of the types (B) is treated with an analyte of unknown activity relative to the parameter by which the sample types differ. The expression profile of treated B is then measured and compared with the expression profiles of A and untreated B to ascertain whether the analyte has induced a shift in the profile of B to more closely or more distantly resemble the profile of A in some meaningful way.

Methods and compositions for reducing the risks of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which induce or increase the risk of one or more adverse CV events, particularly the non-steroidal anti-inflammatory drugs (NSAIDs) and especially the cyclooxygenase-2 (COX-2) inhibitors, are disclosed. The methods involve the administration of compositions comprising the adverse CV event-inducing agent and additional pharmaceutical agents for reducing the risk of adverse CV events. In specific embodiments, the agent is selected from the group consisting of hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins), angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs).

Disclosed herein is a system for providing a user with remote real time access to pharmaceuticals, the system comprising a plurality of carts which accept cassettes that contain pharmaceuticals. The carts preferably contain a CPU which can communicate with a database. A remote CPU is also in electrical communication with the database and may be placed at a pharmacy. When a specific pharmaceutical is required for a specific patient, a user can electronically request a one time access code (OTAC) from the remote CPU. If the request is valid, an OTAC can be sent both electronically to the database in addition to being sent to the user. If the user inputs an OTAC that matches the one stored on the database, the cart is unlocked to provide access to the requested pharmaceutical. Pharmaceuticals that are currently found in the cart can be checked remotely by communicating with the database. A new cassette can then be stocked and sealed by a pharmacist, while another person can transmit the sealed cassette and replace the old cassette within the cart.

The invention discloses a powered cart base for medical care combination, the top of the base is connected with a battery cabinet through fastening bolts, and both ends of one side of the battery cabinet are connected with a door of the battery cabinet through hinges. One side of the battery cabinet is provided with an opening, and the opening is adapted to the door of the battery cabinet, and the inner wall of the bottom of the battery cabinet is connected to equidistantly distributed limiting slide rail groups by fastening bolts. The present invention installs lockers and workbenches on the combined medical care cart, and combines the ordinary nursing cart with the carrying cart of nursing equipment. While classifying and storing medicines and nursing tools, it can also carry medical care through the installation bracket. The equipment is powered by rechargeable batteries for medical care equipment. Three rechargeable batteries and plug-in boards are installed inside the battery cabinet through the limit slide rail group. At the same time, the rechargeable battery is easy to replace, just push the rechargeable battery into the battery cabinet. It can provide stable and long-term power supply for nursing equipment.

A method that creates a new class of pharmaceutical combinations (specific ratio combinations) that offer an improved therapeutic profile with reduced side effects is provided. Safer, more cost-effective drugs for treating various diseases or medical conditions are created by combining receptor activating, inhibiting or modulating drugs in specific ratio combinations that optimize the therapeutic profiles for various pharmaceutical compositions. The method demonstrates how to combine biological or pharmaceutical molecules or drugs in order to create specific ratio combinations that are optimized to improve the overall safety and therapeutic efficacy of the individual molecules or drugs alone. These techniques create novel receptor-activating drugs that are anticipated to prove useful for future therapeutic treatments.

The invention discloses an anticoagulant pharmaceutical monitoring management method based on clinical data. The method is characterized by comprising the following steps: step 1, realizing clinical data acquisition and processing; step 2, realizing group entry evaluation of monitored patients; and step 3, realizing active monitoring and real-time early warning. Patients needing to be subjected toanticoagulation pharmaceutical monitoring can be automatically brought into pharmaceutical monitoring, and automatic, intelligent and active monitoring and real-time early warning are conducted on the monitored patients according to a monitoring early warning model. Therefore, the anticoagulation treatment effect is greatly improved, serious adverse events such as bleeding and stroke are reduced;meanwhile, the anticoagulation pharmacy monitoring work efficiency of clinical pharmacists is greatly improved.

The invention discloses an out-of-hospital pharmaceutical monitoring system and method based on a smart cloud platform, belonging to the technical field of pharmaceutical monitoring. The system comprises an acquisition device for information of a monitored object and a smart cloud platform, wherein the acquisition device for the information of the monitored object is used for acquiring daily monitoring data of the monitored object outside a hospital; the smart cloud platform comprises receiving module for the information of the monitored object, a knowledge base module, a service governance and data distribution module, a data processing module, a data storage module, a data processing and trend prediction module and a pharmacist module. The invention provides the acquisition device for acquisition device for the information of the monitored object, and the smart cloud platform. The acquisition device for the information of the monitored object is an intelligent wristband, an intelligent medicine box, a monitor or the like, the monitored object can use the device for health information acquisition outside the hospital and for logging in the smart cloud platform to obtain pharmaceutical monitoring, so the defect that the monitored object cannot obtain pharmaceutical monitoring outside the hospital is overcome.

The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.

The present invention designs and synthesizes the ascorbyl ester derivatives of the aryl (ethanoic) propanoic acid non-steroidal anti-inflammatory medicaments, such as ibuprofen, ketoprofen and naproxen, and addition salt of the derivatives with pharmaceutical acid or pharmaceutical alkaline. The non-steroidal anti-inflammatory medicament which takes the ibuprofen as the representative is a common antipyretic analgesic medicament. The invention has remarkable antipyretic and analgesic effects and good safety except for anti-inflammatory effect, thus being not only suitable for adults, but also suitable for the elderly people, infants and children. The aryl (ethanoic) propanoic acid ascorbyl ester can be converted into ascorbyl ester derivatives and the addition salts of the derivatives with pharmaceutical acid or pharmaceutical alkaline, which can improve the water solubility thereof, facilitate intravenously administration, reduce the onset time, improve the bioavailability, reduce the stimulation effect to gastrointestinal tract, and enhance the penetrating capacity to hemato encephalic barrier, and can be used as a novel medicament to be applied for antiphlogistic, antipyresis, analgesia, treatment of arthritis, dysmenorrheal, multiple sclerosis, pneumonia cystic fibrosis and patent ductus arteriosus of premature infants, and prevention and treatment of cerebral apoplexy, hypoxic-ischemic brain damage, senile dementia and certain cancers.